Under Armour, Inc. announced its financial results for the second quarter of fiscal 2027, showing a revenue decline of 7% to $1.2 billion. The results, released on November 6, 2026, highlight the ongoing challenges faced by the company and the broader apparel industry.
Kevin Plank, Under Armour's President and CEO, stated, “We delivered against our revenue expectation and exceeded our operating income outlook. As we progress in this transformation, we are driving greater efficiency across our business, sharpening our product offering, and amplifying global marketing to strengthen our brand and improve financial performance.”
Background
Under Armour, Inc. is a prominent player in the apparel industry, specifically categorized under the SIC code 2300, which includes apparel and other finished products of fabrics and similar materials. The company trades on the New York Stock Exchange under the tickers UAA and UA. Its headquarters are located at 101 Performance Drive, Baltimore, Maryland.
What the Filing Says
The filing reveals that Under Armour's revenue decreased to $1.2 billion, with North America revenue also down by 7% to $737 million. The company reported a net loss of $0.4 million for the quarter, with an adjusted net loss of $2 million. The press release detailing these results is included as Exhibit 99.1 in the filing.
Impact
This financial update may affect various stakeholders, including investors, employees, and customers. Investors will be particularly attentive to the company's efforts to improve financial performance amid declining revenues, while employees may be impacted by any restructuring efforts that arise from these challenges.
What's Next
Under Armour has scheduled a conference call for 8:30 a.m. ET on November 6, 2026, to discuss its financial results in greater detail. Further filings may provide additional insights into the company's strategic plans moving forward.
Read Next
Tredegar Corp Reports Q3 2026 Financial Results
Global Partners LP reports strong Q3 2026 financial results
Koppers Holdings Reports Third Quarter 2026 Results
Protara Therapeutics reports quarterly results for Q3 2026
Aligos Therapeutics Reports Q3 Results and Financial Update
Protara Therapeutics Reports Q3 Results, Highlights Trial Progress









